Sophiris Bio to Present at the Stifel Healthcare Conference
SAN DIEGO AND VANCOUVER, Sept. 5, 2013 /PRNewswire/ - Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, President and Chief Executive Officer, will present a corporate overview at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston, Massachusetts. The presentation is scheduled for Thursday, September 12, 2013 at 2:05 pm ET.
The presentation will be webcast live and can be accessed through the Investor Relations page at www.sophiris.com. A replay of the presentation will be available on the Company's website for 90 days.
Sophiris Bio Inc. is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied market with significant market potential. Sophiris' lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris is planning to begin a Phase 3 clinical trial of PRX302 in the second half of 2013.
For more information, please visit www.sophiris.com.
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris' current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Sophiris Bio, Inc.
More by this Source
Sophiris Bio Closes $65 Million Public Offering
Aug 23, 2013, 09:38 ET
Sophiris Bio Prices its Previously Announced Public Offering of Common Shares
Aug 16, 2013, 09:28 ET
Sophiris Bio Announces Share Consolidation
Aug 12, 2013, 16:05 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.